Oxygen
Drug80% versus 30% inspiratory oxygen concentration
NCT Number: NCT03494387
This study examines the risks and benefits of antioxidants and normal versus high inspiratory oxygen fraction during anaesthesia.
Looking for future studies?
Notify Me45 year and older
All sexes
Interventional
Phase 4
Abdominalcentret, Rigshospitalet, Copenhagen, Denmark
Adult patients with risk factors for developing postoperative cardiac complications will be enrolled in the study. The patients will be randomised to receiving antioxidants or placebo perioperatively and 30% or 80% inspiratory oxygen concentration during anaesthesia and 2 hours postoperatively. The primary outcome is MINS (myocardial injury after non-cardiac surgery). The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours, starting at the same time as anaesthesia.
The study is a long-term follow-up study of the risk of mortality, MI and readmissions performed at 1 year after inclusion of the last patient. Two other follow-up studies are planned: One investigation of ischaemic troponin elevations defined as peak troponin levels above the internationally defined thresholds without extracardiac causes; another investigating the intervention effects in the subgroup of patients undergoing vascular surgery with specific emphasis on episodes of intraoperative hypotension within the following thresholds: MAP below 70 mmHg, 65 mmHg, 60 mmHg and 55 mmHg.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All of the listed criteria (1.-4.) must be met.
Exclusion criteria
80% versus 30% inspiratory oxygen concentration
Antioxidants versus placebo
Other names: Ascorbic acid, N-acetylcysteine
Time frame: 30 days
Troponin measurement the first 3 postoperative days. Assessed by area under the curve.
Time frame: During the study period until completion of last visit of last patient
Assessed as time to event analysis
Time frame: During the study period until completion of last visit of last patient
Assessed as time to event analysis
Time frame: During the study period until completion of last visit of last patient
Assessed as time to event analysis
Time frame: Assessed at postoperative day 30
Infection in surgical area as defined by the Center for Disease Control
Time frame: Assessed at postoperative day 30
Pneumonia as defined by the Center for Disease Control
Time frame: Assessed at postoperative day 30
Sepsis as defined by the joint task force by the European Society of Intensive Care Medicine and the Society of Critical Care Medicine
Time frame: Assessed at postoperative day 30
Acute respiratory failure defined as the need for controlled ventilation or oxygen saturation of 900% or less despite of oxygen therapy
Time frame: Assessed at postoperative day 30
Acute kidney injury as defined Kidney Disease Improving Global Outcomes guidelines
University Hospital Bispebjerg and Frederiksberg
Other
Hyperoxia and Antioxidants During Major Non-cardiac Surgery and Risk of Cardiovascular Complications, a Blinded 2x2 Factorial Randomised Clinical Trial
Acronym: VIXIE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01510652
Cardiovascular Diseases, Heart Diseases
Genk, Belgium
View Trial DetailsNCT05354648
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT07369232
Antioxidant, Cerebral Autoregulation
Anderlecht, Brussels Capital, Belgium
View Trial DetailsNCT07551869
HIIT, High Intensity Interval Training
Brussels, Brussels Capital, Belgium
View Trial Details